- Primary research
- Open Access
Inhibition of androgen-independent prostate cancer cell growth is enhanced by combination therapy targeting Hedgehog and ErbB signalling
© Shaw and Prowse; licensee BioMed Central Ltd. 2008
- Received: 07 November 2007
- Accepted: 18 March 2008
- Published: 18 March 2008
Prostate cancer is a leading cause of male cancer specific mortality. When cure by radical prostatectomy is not possible the next line of prostate cancer treatment is androgen deprivation. However prolonged androgen deprivation often results in relapse and androgen-independent prostate cancer that is inevitably fatal despite optimal chemotherapy. The Hedgehog signalling pathway has recently been implicated in prostate cancer development and metastasis. EGFR or ErbB2 expression has been also correlated with androgen independence, shorter survival and metastasis.
We determined that the Hedgehog and ErbB signalling pathways are active in circulating tumour cells isolated from androgen-independent prostate cancer patients and in the androgen-independent prostate cancer cell line LNCaP C4-2B. As a basis for synergistic chemotherapy protocols combinations of the Hedgehog specific inhibitor cyclopamine and the ErbB signalling inhibitors gefitinib or lapatinib were tested in this study. Androgen-independent prostate cancer cell growth was inhibited by a SMO inhibitor (cyclopamine) which blocks Hedgehog signalling and by ErbB inhibitors (gefitinib and lapatinib). The isobologram and combination index method of Chou and Talalay was used to evaluate drug interactions. Synergistic antiproliferation effects were observed when the Hedgehog and ErbB inhibitors were combined.
Androgen-independent prostate cancer cell proliferation was associated with activity of the Hedgehog and ErbB signalling pathways. Cyclopamine, gefitinib or lapatinib treatment significantly decreased the proliferation of androgen-independent prostate cancer cells. The Hedgehog pathway therefore represents a promising new therapeutic target in androgen-independent prostate cancer. Synergistic effects were observed when Hedgehog and ErbB inhibitors were used together. This study may have clinical implications for improving the treatment of advanced prostate cancer.
- Prostate Cancer
- Androgen Receptor
- Circulate Tumour Cell
Prostate cancer is a leading cause of male cancer related deaths  and autopsy series have also found prostate carcinomas in the majority of men aged 60 to 70 years . The incidence of prostate cancer diagnosis is also increasing as awareness improves, PSA measurement is performed more frequently and life expectancy increases . Testicular factors were first linked to prostatic growth by John Hunter in 1786, although the endocrine nature of the relationship was not appreciated. Castration was subsequently shown by Charles Huggins in the 1940s to result in shrinkage of prostate cancer metastasis. Decreasing circulating testosterone with androgen deprivation therapy is currently used to treat metastatic prostate cancer and those cancers that are not suitable for attempts at cure with radiotherapy or surgery. This effectively shrinks androgen-dependent tumours, both in the prostate and at distant sites. However many men ultimately fail this therapy and continuous androgen deprivation usually leads to recurrent androgen-independent prostate cancer (AIPC). Once AIPC develops the median survival with the most effective therapeutic regimes is 20–24 months [4, 5]. The high mortality rate associated with prostate cancer is therefore linked to the development of AIPC and the current lack of effective therapies. Developing new therapeutic approaches that target AIPC therefore has considerable potential for improving quality of life and survival of patients with advanced prostate cancer.
AIPC that arises as a consequence of androgen deprivation therapy may be due to increased activity of the androgen receptor (AR) or cell signalling pathways . Growth factor signalling has been linked to ligand independent activity of the AR . The ErbB receptor family are transmembranous receptors including EGFR, ErbB2, ErbB3 and ErbB4 which have intracellular tyrosine kinase domains. EGFR or ErbB2 expression has been correlated with androgen independence, shorter survival and metastasis [6–9]. Specific inhibitors of ErbB tyrosine kinase receptors have been developed. Gefitinib (Astra-Zeneca) is an EGFR receptor antagonist and lapatinib (Glaxo-Smithkline) has kinase inhibitor activity, inhibiting EGFR and ErbB2 activity. However their results in advanced prostate cancer trials to date have not been promising with the authors of one trial concluding that "gefitinib has minimal single-agent activity in AIPC" .
The Hedgehog pathway has also recently been implicated in prostate cancer development and metastasis . Patched (PTCH) is the receptor for Hedgehog ligands (Sonic, Indian and Desert), which in the absence of Hedgehog inhibits Smoothened (SMO), a G protein coupled-like receptor. When Hedgehog binds to PTCH, SMO is disinhibited and initiates a signalling cascade that results in activation of GLI transcription factors and increased expression of target genes (including PTCH and GLI1). Inhibition of the Hedgehog pathway induces apoptosis and decreases invasiveness of prostate cancer cells . Recent studies have shown a high prevalence of Hedgehog activity in high grade or metastatic prostate cancers [11, 12], but the contribution of Hedgehog signalling to AIPC is unclear.
To clarify the role of ErbB and Hedgehog signalling in AIPC we determined that these pathways are active in both circulating tumour cells (CTC) isolated from patients with androgen-independent prostate cancer and in the androgen-independent prostate cancer cell line LNCaP C4-2B. The specific hedgehog pathway inhibitor cyclopamine and the ErbB pathway inhibitors gefitinib or lapatinib significantly decreased the proliferation of androgen-independent prostate cancer cells. A synergistic effect of Hedgehog and ErbB inhibitors on prostate cancer cell growth was also observed, consistent with both Hedgehog and ErbB signalling contributing to the proliferation of androgen-independent prostate cancer cells. The Hedgehog pathway therefore represents a promising new therapeutic target in androgen-independent prostate cancer.
Dose-effect relationships of drug combinations in human androgen-independent prostate cancer cell line LNCaP C4-2B: Gefitinib (Ge), Lapatinib (La) and Cyclopamine (Cy).
CI value at
This is consistent with the antiproliferative results recently reported following treatment with cyclopamine or gefitinib of androgen dependent LNCaP-C33 cells, the spontaneously arising androgen-independent LNCaP subline C81 and androgen independent DU145 and PC3 cells [21, 25]. Importantly, combined cyclopamine and gefitinib treatment was also found to cause a high rate of inhibition of proliferation  and a significant increase in apoptotic death of androgen-independent LNCaP-C81, DU145 and PC3 cells, although androgen dependent LNCaP-C33 cells were less responsive to these agents . Our CTC analysis is also consistent with reports that specimens from advanced prostate cancer have higher levels of SHH, PTCH-1 and GLI-1 as compared to samples from localized PC and normal tissues or benign PrE cells [11, 21, 26].
The synergy between cyclopamine and gefitinib or lapatinib may occur because of interactions between the Hedgehog and ErbB pathways, consistent with EGF signalling selectively enhancing Hedgehog activity  and cyclopamine treatment of PC3 cells causing downregulation of EGFR expression . Gefitinib has also been reported to inhibit the activity of the androgen receptor, enhancing its anti-proliferative affect . Hedgehog and ErbB signalling may also contribute to prostate cancer metastatsis as we have found expression of these genes in CTC isolated from the peripheral blood of AIPC patients, gefitinib treatment has been reported to inhibit EGF induced invasion of prostate cancer cells  and Hedgehog signalling has also been linked to metastasis [11, 12]. Combination chemotherapy targeting these signalling pathways therefore also has the potential to be beneficial in metastatic prostate cancer.
Our findings are consistent with Hedgehog and ErbB being of therapeutic relevance to the management of prostate cancer. Hedgehog signalling may be an important new target in metastatic AIPC. Although, at present, there is no clinically available treatment that specifically targets the Hedgehog signalling pathway. The SMO inhibitor cyclopamine, which we show can be used to inhibit AIPC cell proliferation, along with other Hedgehog signalling targeting compounds are currently being developed (Curis, USA) and a Phase I clinical trial of a systemically administered small molecule Hedgehog antagonist initiated (Genentech, USA). In addition, as significant clinical improvements have not been reported using ErbB signalling inhibitors alone (Herceptin or Gefitinib) in phase II clinical trials for advanced prostate cancer [10, 30]. Combination therapy targeting both Hedgehog and ErbB signalling may enable enhanced anticancer efficacy with no greater toxicity, thus improving the treatment of advanced prostate cancer.
Our results suggest that the Hedgehog and ErbB signalling may play an important role in the proliferation of androgen-independent prostate cancer cells. As we observed expression of PTCH, GLI1, EGFR and ErbB2 in AIPC cells and that inhibitors of these signalling pathways in combination had synergistic anti-proliferative effects. The Hedgehog pathway therefore represents a potential new therapeutic target in advanced prostate cancer and combination therapy against Hedgehog and ErbB pathways could also be considered.
Cell and tissue culture
Androgen-dependent LNCaP cells were obtained from the American Type Culture Collection (ATCC). Androgen-independent LNCaP C4-2B cells were purchased from Viromed Laboratories. Cells were grown at 37°C in RPMI media without phenol red (Sigma) supplemented with 10% (v/v) fetal bovine serum (Invitrogen) or 10% (v/v) charcoal stripped FBS (Hyclone), 2.4 mM glutamine (Sigma), 1% (v/v) pyruvate (Sigma), penicillin and streptomycin (50 U and 50 μg/ml) (Invitrogen). Cells were treated with EGF (Sigma), cyclopamine (Sigma), gefitinib (AstraZenica) and lapatinib (Glaxo-Smithkline) as detailed.
Isolation of circulating tumour cells
Peripheral blood samples were obtained from 15 patients (anonymised for confidentiality according to the format ABC 12) and 5 normal male subjects (named NORM 1–5, all under 40 years of age with no significant intercurrent illness). Two 10 ml peripheral blood samples were collected in EDTA coated tubes (Greiner), kept on ice and processed within three hours of collection. Samples were processed through Oncoquick (Greiner) tubes, as per the manufacturer's instructions. In order to further purify the CTC the Oncoquick enriched samples were depleted of CD45 positive cells and positively selected for EpCAM expressing cells using AutoMACS™ (Miltenyi biotech). The study was fully approved by the Local Research Ethics Committee (reference number 05/Q0602/48).
RNA isolation, amplification, reverse transcription and quantitative PCR
Oligonucleotides used for PCR amplification
Size of product (Base Pairs)
Antibodies and immunoblotting
Primary antibodies used were as follows: EGFR (#2232 Cell Signalling); Phospho-EGFR (#2231 Cell Signalling); Phospho-ErbB2 (#2241 Cell Signalling); Patched (#sc-6149 Santa Cruz Biotechnology); EpCAM (#ab20160 Abcam) and GAPDH (# ab9485 Abcam). For immunofluoresence staining CTCs were air dried onto slides, fixed with methanol and incubated with primary antibodies (1:400 phospho-EGFR; 1:250 Phospho-ErbB2; 1:250 EpCAM; 1:200 Patched) overnight in blocking buffer and detected using appropriate secondary antibodies. Nuclear counterstaining was performed using DAPI. Stained preparations were analysed on a Zeiss 510 confocal microscope. For western blotting cultured cells at 70–80% confluence were washed twice with PBS and lysed in RIPA buffer containing Sigma Phosphatase Inhibitor Cocktails I & II and Roche Protease Inhibitor Complete EDTA-free. Lysates were cleared by centrifugation at 16,000 × g for 10 mins. 20 ug of each lysate was boiled for 10 mins in Invitrogen sample buffer with antioxidant and resolved using the Invitrogen NuPage system on a 10% Bis-Tris gel with MOPS buffer, then transferred to Amersham Hybond-C extra membrane. The membranes were blocked for 30 mins in 5% milk or 5% BSA (GAPDH) in TBS-T. Primary antibodies (1:1000 pEGFR and pEGFR; 1:5000 GAPDH) were incubated overnight at 4°C with blocking and visualised using an appropriate HRP-conjugated secondary antibody using enhanced chemiluminescence (ECL, Amersham).
MTT assay for cell proliferation
The MTT [3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide] assay is based on the ability of a mitochondrial dehydrogenase enzyme from viable cells to cleave the tetrazolium rings of the pale yellow MTT and form dark blue formazan crystals which are largely impermeable to cell membranes, thus resulting in its accumulation within viable cells. The colour can then be quantified using a simple colorimetric assay. Cells were seeded onto 96 well plates at 2–4 × 104/well in 200 μl media and synchronized in G0 (quiescent) phase of the growth cycle by culture in serum free medium. After 12 hours this serum free medium was replaced with 10% Fetal Bovine Serum in RPMI containing inhibitors as detailed. After 48 hours 20 μl of the 5 mg/ml MTT substrate was added to each well. Plates were returned to the incubator and left in the dark for 1 hour. After the incubation period, MTT substrate/medium was gently removed from each well and 200 μl of DMSO were added to each well to dissolve the MTT formazan crystals and absorbance measured spectrophotometrically at a wavelength of 570 nm. Blank control values were then subtracted from the 570 nm values and relative growth rates were calculated. All experiments carried out using MTT assay were carried out on three separate occasions.
Determination of IC50 concentration for cytotoxic drugs
Androgen-independent LNCaP C4-2B cells growing in androgen free medium were harvested by trypsinisation, washed and seeded at 30,000 per well in 96 well plates and left to attach overnight. The IC50 doses were determined by exposing cells to various concentrations of the drugs 10-7–10-3M for 72 hours. The medium with drug was aspirated and the MTT assay described above was performed. The IC50 was defined as the concentration of drug at which there was a 50% less growth when compared to control cells. Each experiment was performed in triplicate.
Median effect analysis
The isobologram and combination index (CI) were calculated according to the Chou and Talalay median effect principal  using Calcusyn software (Biosoft). The drugs were applied at a fixed ratio of the IC50 across a range of activities and viability was evaluated using the MTT assay at each dosage. Data from cell viability assay were expressed as the fraction of cells inhibited by drug treatments compared with untreated cells. Interaction between pairs of drugs was determined using the Calcusyn computed isolobogram and combination index (CI). The isobologram is a graphical representation of the interaction between two drugs and is formed by plotting the individual drug doses required to achieve a single agent effect on their respective x and y axes, a line connecting the two points is drawn and the concentrations of the two drugs used in combination to achieve the same effect are plotted on the isobologram. Combination data points that fall on the line represent an additive interaction, whereas points above or below represent antagonism or synergy respectively. The CI analysis is similar to the isobologram provides qualitative information on the drug interaction and a numerical CI value is calculated based on the following equation: CI = (D)1/(Dx)1 + (D)2/(Dx)2 + (D)1(D)2/(Dx)1(Dx)2, where (D)1 and (D)2 are the doses of drug 1 and drug 2 that have x% effect when used in combination, and (Dx)1 and (Dx)2 are the doses of drug 1 and drug 2 that have the same x% effect when used alone. The CI indicates synergism when <0.9, antagonism when >1.1 and additivity when 0.9–1.1. The Calcusyn software also calculates the median effect dose (D m ) of each combination, shape of the dose-effect curve (m) and linear correlation coefficient of the median effect plot (r) indicating conformity of date.
We would like to thank Ms Elena Ktori, Ms Siobhan McFaul and Ms Trisha Purkis for assistance with CTC preparations and Dr Simon Joel for his help with Calcusyn. This research was supported by a grant from the Orchid Cancer Appeal, London, UK. DMP is a Research Council UK academic fellow.
- Carson CC: Carcinoma of the prostate: overview of the most common malignancy in men. N C Med J. 2006, 67 (2): 122-127.PubMedGoogle Scholar
- Sakr WA, Grignon DJ, Crissman JD, Heilbrun LK, Cassin BJ, Pontes JJ, Haas GP: High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo. 1994, 8 (3): 439-443.PubMedGoogle Scholar
- Shaw GL, Wilson P, Cuzick J, Prowse DM, Goldenberg SL, Spry NA, Oliver T: International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients. BJU Int. 2007, 99 (5): 1056-1065. 10.1111/j.1464-410X.2007.06770.x.View ArticlePubMedGoogle Scholar
- Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004, 351 (15): 1513-1520. 10.1056/NEJMoa041318.View ArticlePubMedGoogle Scholar
- Shamash J, Dancey G, Barlow C, Wilson P, Ansell W, Oliver RT: Chlorambucil and lomustine (CL56) in absolute hormone refractory prostate cancer: re-induction of endocrine sensitivity an unexpected finding. Br J Cancer. 2005, 92 (1): 36-40. 10.1038/sj.bjc.6602263.PubMed CentralView ArticlePubMedGoogle Scholar
- Mimeault M, Batra SK: Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis. 2006, 27 (1): 1-22. 10.1093/carcin/bgi229.View ArticlePubMedGoogle Scholar
- Shi Y, Brands FH, Chatterjee S, Feng AC, Groshen S, Schewe J, Lieskovsky G, Cote RJ: Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. J Urol. 2001, 166 (4): 1514-1519. 10.1016/S0022-5347(05)65822-3.View ArticlePubMedGoogle Scholar
- Shah RB, Ghosh D, Elder JT: Epidermal growth factor receptor (ErbB1) expression in prostate cancer progression: correlation with androgen independence. Prostate. 2006, 66 (13): 1437-1444. 10.1002/pros.20460.View ArticlePubMedGoogle Scholar
- Nishio Y, Yamada Y, Kokubo H, Nakamura K, Aoki S, Taki T, Honda N, Nakagawa A, Saga S, Hara K: Prognostic significance of immunohistochemical expression of the HER-2/neu oncoprotein in bone metastatic prostate cancer. Urology. 2006, 68 (1): 110-115. 10.1016/j.urology.2006.01.060.View ArticlePubMedGoogle Scholar
- Canil CM, Moore MJ, Winquist E, Baetz T, Pollak M, Chi KN, Berry S, Ernst DS, Douglas L, Brundage M, Fisher B, McKenna A, Seymour L: Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol. 2005, 23 (3): 455-460. 10.1200/JCO.2005.02.129.View ArticlePubMedGoogle Scholar
- Karhadkar SS, Bova GS, Abdallah N, Dhara S, Gardner D, Maitra A, Isaacs JT, Berman DM, Beachy PA: Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature. 2004, 431 (7009): 707-712. 10.1038/nature02962.View ArticlePubMedGoogle Scholar
- Datta S, Datta MW: Sonic Hedgehog signaling in advanced prostate cancer. Cell Mol Life Sci. 2006, 63 (4): 435-448. 10.1007/s00018-005-5389-4.View ArticlePubMedGoogle Scholar
- Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, Fritsche HA, Hortobagyi GN, Terstappen LW: Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol. 2005, 23 (7): 1420-1430. 10.1200/JCO.2005.08.140.View ArticlePubMedGoogle Scholar
- Moreno JG, Miller MC, Gross S, Allard WJ, Gomella LG, Terstappen LW: Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology. 2005, 65 (4): 713-718. 10.1016/j.urology.2004.11.006.View ArticlePubMedGoogle Scholar
- O'Hara SM, Moreno JG, Zweitzig DR, Gross S, Gomella LG, Terstappen LW: Multigene reverse transcription-PCR profiling of circulating tumor cells in hormone-refractory prostate cancer. Clin Chem. 2004, 50 (5): 826-835. 10.1373/clinchem.2003.028563.View ArticlePubMedGoogle Scholar
- van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ, Lucia MS: Molecular characterization of human prostate carcinoma cell lines. Prostate. 2003, 57 (3): 205-225. 10.1002/pros.10290.View ArticlePubMedGoogle Scholar
- Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung LW: Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res. 1994, 54 (10): 2577-2581.PubMedGoogle Scholar
- Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T: Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 2001, 61 (9): 3550-3555.PubMedGoogle Scholar
- Litvinov IV, De Marzo AM, Isaacs JT: Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling?. J Clin Endocrinol Metab. 2003, 88 (7): 2972-2982. 10.1210/jc.2002-022038.View ArticlePubMedGoogle Scholar
- Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW, Srivastava S: Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res. 1994, 54 (11): 2861-2864.PubMedGoogle Scholar
- Mimeault M, Moore E, Moniaux N, Henichart JP, Depreux P, Lin MF, Batra SK: Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in prostate cancer cells. Int J Cancer. 2006, 118 (4): 1022-1031. 10.1002/ijc.21440.View ArticlePubMedGoogle Scholar
- Liu Y, Majumder S, McCall W, Sartor CI, Mohler JL, Gregory CW, Earp HS, Whang YE: Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Cancer Res. 2005, 65 (8): 3404-3409.PubMedGoogle Scholar
- Festuccia C, Gravina GL, Angelucci A, Millimaggi D, Muzi P, Vicentini C, Bologna M: Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro. Int J Cancer. 2005, 115 (4): 630-640. 10.1002/ijc.20917.View ArticlePubMedGoogle Scholar
- Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984, 22: 27-55. 10.1016/0065-2571(84)90007-4.View ArticlePubMedGoogle Scholar
- Mimeault M, Venkatraman G, Johansson SL, Moore E, Henichart JP, Depreux P, Lin MF, Batra SK: Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide. Int J Cancer. 2007, 120 (1): 160-169. 10.1002/ijc.22268.View ArticlePubMedGoogle Scholar
- Sheng T, Li C, Zhang X, Chi S, He N, Chen K, McCormick F, Gatalica Z, Xie J: Activation of the hedgehog pathway in advanced prostate cancer. Mol Cancer. 2004, 3: 29-10.1186/1476-4598-3-29.PubMed CentralView ArticlePubMedGoogle Scholar
- Kasper M, Schnidar H, Neill GW, Hanneder M, Klingler S, Blaas L, Schmid C, Hauser-Kronberger C, Regl G, Philpott MP, Aberger F: Selective modulation of Hedgehog/GLI target gene expression by epidermal growth factor signaling in human keratinocytes. Mol Cell Biol. 2006, 26 (16): 6283-6298. 10.1128/MCB.02317-05.PubMed CentralView ArticlePubMedGoogle Scholar
- Sugita S, Kawashima H, Tanaka T, Kurisu T, Sugimura K, Nakatani T: Effect of type I growth factor receptor tyrosine kinase inhibitors on phosphorylation and transactivation activity of the androgen receptor in prostate cancer cells: Ligand-independent activation of the N-terminal domain of the androgen receptor. Oncol Rep. 2004, 11 (6): 1273-1279.PubMedGoogle Scholar
- Bonaccorsi L, Carloni V, Muratori M, Formigli L, Zecchi S, Forti G, Baldi E: EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR). Int J Cancer. 2004, 112 (1): 78-86. 10.1002/ijc.20362.View ArticlePubMedGoogle Scholar
- Ziada A, Barqawi A, Glode LM, Varella-Garcia M, Crighton F, Majeski S, Rosenblum M, Kane M, Chen L, Crawford ED: The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate. 2004, 60 (4): 332-337. 10.1002/pros.20065.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.